Lantheus Holdings, Inc. (NASDAQ:LNTH) Receives $122.50 Consensus Target Price from Brokerages

Lantheus Holdings, Inc. (NASDAQ:LNTH) has been given an average rating of “Moderate Buy” by the eight research firms that are presently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $125.71.

A number of equities research analysts have commented on the company. Redburn Atlantic assumed coverage on Lantheus in a report on Tuesday, September 3rd. They set a “buy” rating and a $175.00 price target on the stock. Truist Financial reissued a “buy” rating and issued a $120.00 price objective (down from $135.00) on shares of Lantheus in a research note on Friday, November 8th. JMP Securities cut their target price on Lantheus from $125.00 to $112.00 and set a “market outperform” rating on the stock in a research report on Thursday, November 7th. Finally, StockNews.com lowered shares of Lantheus from a “buy” rating to a “hold” rating in a research report on Thursday, November 21st.

Lantheus Price Performance

Shares of Lantheus stock opened at $89.27 on Monday. Lantheus has a 1-year low of $50.20 and a 1-year high of $126.89. The company’s fifty day simple moving average is $101.34 and its 200-day simple moving average is $97.37. The stock has a market capitalization of $6.21 billion, a PE ratio of 14.85 and a beta of 0.51.

Institutional Trading of Lantheus

Large investors have recently added to or reduced their stakes in the company. Tidal Investments LLC increased its holdings in Lantheus by 25.2% in the 3rd quarter. Tidal Investments LLC now owns 17,621 shares of the medical equipment provider’s stock worth $1,934,000 after buying an additional 3,547 shares during the period. Wilmington Savings Fund Society FSB purchased a new position in shares of Lantheus during the third quarter worth $25,000. World Investment Advisors LLC purchased a new position in shares of Lantheus during the third quarter worth $60,000. Hohimer Wealth Management LLC acquired a new position in Lantheus during the third quarter valued at $250,000. Finally, Coldstream Capital Management Inc. purchased a new position in shares of Lantheus during the 3rd quarter valued at about $230,000. Hedge funds and other institutional investors own 99.06% of the company’s stock.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.